文献速递免疫规划

巴西单剂水痘疫苗有效性:病例对照研究

Single-dose varicella vaccine effectiveness in Brazil: A case-control study.
PubMed 文献 · Vaccine · 2017-12-14

巴西于2013年10月将单剂水痘疫苗纳入免疫规划,在15月龄接种。本研究在圣保罗和戈亚尼亚开展匹配病例对照研究,纳入168例病例和301名对照。单剂疫苗对任何严重程度疾病的有效性为86%(95%CI 72-92%),对中重度疾病为93%(95%CI 82-97%)。

要点

  • 单剂水痘疫苗对任何严重程度疾病有效性86%(95%CI 72-92%)
  • 对中重度疾病有效性93%(95%CI 82-97%)
  • 突破性病例较非突破性病例病情更轻(p < .001)

核心结论

  • 巴西单剂水痘疫苗有效性与其它已发现突破性病例的国家相当。
  • 考虑将第二剂水痘疫苗纳入国家免疫规划时,应结合疫苗接种规划的目标、疾病负担和可负担性。

研究设计与样本

  • 匹配病例对照研究,在巴西圣保罗和戈亚尼亚开展。
  • 通过研究现场建立的前瞻性监测识别疑似病例,所有病例采集皮肤病变标本进行分子实验室检测。
  • 病例经临床或皮肤病变PCR确诊,分为轻度、中度和重度疾病。
  • 每例病例匹配2名邻居对照,病例和对照年龄15-32月龄,在家访谈。
  • 疫苗接种证据来自接种卡,使用单因素和多因素logistic回归模型估计比值比及其95%置信区间。

主要发现

  • 共纳入168例病例和301名对照。
  • 33.3%的病例为中度疾病,9.9%为重度疾病。
  • 单剂水痘疫苗对任何严重程度疾病的有效性为86%(95%CI 72-92%)。
  • 对中重度疾病的有效性为93%(95%CI 82-97%)。
  • 168例病例中,81.8%野生型株PCR阳性,22.0%为突破性水痘病例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Varicella vaccine was introduced into the Brazilian Immunization Program in October 2013, as a single-dose schedule administered at 15 months of age. Its effectiveness had not yet been assessed in the country. METHODS: A matched case-control study was carried out in São Paulo and Goiânia (Southeast and Midwest regions, respectively), Brazil. Suspected cases, were identified through a prospective surveillance established in the study sites. All cases had specimens from skin lesion collected for molecular laboratory testing. Cases were confirmed by either clinical or PCR of skin lesions and classified as mild, moderate, and severe disease. Two neighborhood controls were selected for each case. Cases and controls were aged 15-32 months and interviewed at home. Evidence of prior vaccination was obtained from vaccination cards. Univariate and multivariate logistic regression models were used, and odds ratio and its respective 95% confidence intervals were estimated. Vaccine effectiveness was estimated by comparing de odds of having received varicella vaccine among cases and controls. RESULTS: A total of 168 cases and 301 controls were enrolled. Moderate and severe illness, was found in 33.3% and 9.9% of the cases. Effectiveness of a single dose varicella vaccine was 86% (95%CI 72-92%) against disease of any severity and 93% (95%CI 82-97%) against moderate and severe disease. Out of 168 cases, 81.8% had positive PCR results for wild-type strains, and 22.0% were breakthrough varicella cases. Breakthrough cases were milder compared to non-breakthrough cases (p < .001). CONCLUSIONS: Effectiveness of single dose varicella vaccine in Brazil is comparable to that in other countries where breakthrough varicella cases have also been found to occur. The goal of the varicella vaccination program, along with disease burden and affordability should be taken into consideration when considering the adoption of a second dose of varicella vaccine into national immunization programs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Andrade AL, da Silva Vieira MA, Minamisava R, et al. Single-dose varicella vaccine effectiveness in Brazil: A case-control study. Vaccine. 2017. PMID: 29249544. doi:10.1016/j.vaccine.2017.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。